Glaukos Co. (NYSE:GKOS) Shares Acquired by GAMMA Investing LLC

GAMMA Investing LLC grew its position in Glaukos Co. (NYSE:GKOS - Free Report) by 5,912.8% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 133,064 shares of the medical instruments supplier's stock after acquiring an additional 130,851 shares during the period. GAMMA Investing LLC owned about 0.24% of Glaukos worth $13,096,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. State of Wyoming raised its position in shares of Glaukos by 2.3% in the fourth quarter. State of Wyoming now owns 3,245 shares of the medical instruments supplier's stock worth $487,000 after acquiring an additional 72 shares during the period. Quadrant Capital Group LLC raised its position in shares of Glaukos by 3.3% in the fourth quarter. Quadrant Capital Group LLC now owns 2,300 shares of the medical instruments supplier's stock worth $345,000 after acquiring an additional 73 shares during the period. Mutual of America Capital Management LLC raised its position in shares of Glaukos by 1.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier's stock worth $1,252,000 after acquiring an additional 89 shares during the period. HighTower Advisors LLC raised its position in shares of Glaukos by 2.8% in the fourth quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier's stock worth $495,000 after acquiring an additional 91 shares during the period. Finally, Handelsbanken Fonder AB increased its stake in shares of Glaukos by 0.7% during the fourth quarter. Handelsbanken Fonder AB now owns 14,700 shares of the medical instruments supplier's stock worth $2,204,000 after purchasing an additional 100 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.

Glaukos Stock Performance

Glaukos stock opened at $93.04 on Friday. The firm has a 50 day simple moving average of $91.84 and a 200-day simple moving average of $121.54. Glaukos Co. has a 1-year low of $77.10 and a 1-year high of $163.71. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The stock has a market cap of $5.32 billion, a price-to-earnings ratio of -32.42 and a beta of 0.80.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $106.66 million during the quarter, compared to analysts' expectations of $102.78 million. During the same quarter in the prior year, the company posted ($0.70) EPS. The business's revenue for the quarter was up 24.6% on a year-over-year basis. On average, analysts expect that Glaukos Co. will post -1.08 EPS for the current year.

Insider Transactions at Glaukos

In other news, CFO Alex R. Thurman sold 1,520 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the transaction, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. This represents a 2.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 5.80% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on GKOS shares. Truist Financial reissued a "buy" rating and set a $135.00 target price (down previously from $140.00) on shares of Glaukos in a research note on Thursday, May 1st. Mizuho cut their target price on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a research note on Wednesday, April 16th. Piper Sandler cut their target price on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating for the company in a research note on Tuesday, April 15th. Morgan Stanley cut their target price on shares of Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Finally, Needham & Company LLC cut their target price on shares of Glaukos from $176.00 to $115.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, Glaukos has a consensus rating of "Moderate Buy" and an average target price of $134.67.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.